<DOC>
	<DOC>NCT00658905</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy in preterm infants following treatment with BSSL when administered in infant formula.</brief_summary>
	<brief_title>Efficacy and Safety of Bile Salt Stimulated Lipase (BSSL) as Replacement Therapy in Infant Formula for Preterm Infants</brief_title>
	<detailed_description>In this double-blind crossover study, patients will be randomized to receive infant formula including BSSL or infant formula without BSSL for the first 7 days. After a wash-out period of 2 days the patients will "crossover" to the other treatment regimen and receive an additional 7 days treatment. The primary efficacy measurements will be made by collecting stool during the last three days of each treatment period.</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<criteria>Preterm infants less than or equal to 32 weeks of gestational age appropriate for gestational age enterally fed with infant formula</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>32 Weeks</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Preterm infants</keyword>
	<keyword>Replacement therapy</keyword>
	<keyword>Infant formula</keyword>
	<keyword>BSSL</keyword>
	<keyword>BSSL is present in fresh mother's milk but not in infant formula.</keyword>
</DOC>